Cardiovascular Outcomes of Diabetes Pharmacotherapy
Summary
Cardiovascular disease remains the leading cause of morbidity and mortality in people with diabetes, prompting rigorous evaluation of glucose-lowering therapies for their cardioprotective benefits and safety. Modern pharmacotherapy spans several classes, including glucagon-like peptide-1 receptor agonists, sodium–glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors, each with distinct mechanisms that influence vascular function, haemodynamic load and myocardial metabolism. Landmark cardiovascular outcome trials have established that certain agents reduce major adverse cardiovascular events, heart failure hospitalisation and all-cause mortality, while others demonstrate neutral or potentially adverse effects. Treatment selection now considers both glycaemic control and organ protection, integrating risk stratification for atherosclerotic disease, heart failure and chronic kidney disease. Beyond individual drug effects, network meta-analyses and real-world studies inform comparative effectiveness, guiding guideline recommendations towards use of therapies with proven cardiovascular benefits. Globally, these advances herald a paradigm shift in diabetes care, from glucose-centric management to comprehensive cardio-renal protection, with implications for clinical practice, health policy and patient outcomes.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Cardiovascular Outcomes of Diabetes Pharmacotherapy publication trend
The graph below shows the total number of articles in cardiovascular outcomes of diabetes pharmacotherapy across all publications each year (not limited to Nature Index journals).
Technical terms
Major adverse cardiovascular events (MACE): Composite end point including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.
Glucagon-like peptide-1 receptor agonists: Agents that mimic the incretin hormone GLP-1 to enhance insulin secretion, delay gastric emptying and exert cardioprotective effects.
Sodium–glucose co-transporter-2 inhibitors: Drugs that block renal reabsorption of glucose and sodium, lowering blood glucose and reducing cardiovascular and heart failure risks.
Dipeptidyl peptidase-4 inhibitors: Medications that prevent degradation of incretins, modestly improving glycaemia without demonstrated cardiovascular benefit.
Hazard ratio: Statistic expressing the relative rate of an event occurring in a treatment group compared with a control group over time.
Chronic kidney disease (CKD): Progressive impairment of renal function, defined by reduced estimated glomerular filtration rate or increased albuminuria.
Albuminuria: Pathological excretion of albumin in urine, indicating glomerular damage and elevated cardiovascular risk.
Estimated glomerular filtration rate (eGFR): Calculated index of kidney filtration capacity, used to stage renal dysfunction.
References
- Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. European Heart Journal (2024).
- Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovascular Diabetology (2019).
- Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke (2022).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.